Columbia University Medical Center/New York-Presbyterian Hospital and the Cardiovascular Research Foundation, New York, New York 10032, USA.
JACC Cardiovasc Interv. 2011 Aug;4(8):861-7. doi: 10.1016/j.jcin.2011.05.019.
This study sought to evaluate the technical success and clinical outcomes of an adjunctive crossover balloon occlusion technique (CBOT) combined with the 10-F Prostar percutaneous closure device (PCD) on the incidence of vascular and bleeding complications in patients after transfemoral transcatheter aortic valve implantation (TAVI).
Vascular closure following large-vessel access has most commonly been performed using a surgical cut-down and repair procedure.
Between November 2008 and September 2010, 58 consecutive patients with severe aortic stenosis underwent TAVI via a retrograde femoral artery approach using the Edwards-SAPIEN transcatheter valve. Among these patients, 56 were treated with a CBOT using the "pre-close" technique and the 10-F Prostar system. The technical success of this new CBOT and the 30-day frequency of clinical events, including all-cause mortality, major vascular complications, and major bleeding (defined according to a modified version of the Valve Academic Research Consortium criteria), were assessed.
Successful closure was obtained in all but 3 patients (94.6%). The 30-day frequencies of mortality, major vascular complications, and major bleeding were 7.1%, 14.3%, and 5.4% respectively. No deaths were directly related to access site complications. Fourteen patients (25%) received at least 1 transfusion during the index hospitalization, of which 8 (57.1%) were not related to vascular complications. The mean and median hospital lengths of stay were 7.8 and 6.0 days.
This new percutaneous adjunctive CBOT combined with the Prostar PCD resulted in controlled, safe, and successful percutaneous closure in most patients after TAVI.
本研究旨在评估经股动脉逆行入路行经导管主动脉瓣置换术(TAVI)后,附加交叉球囊阻断技术(CBOT)联合 10-F Prostar 经皮封堵器(PCD)对血管和出血并发症发生率的技术成功和临床结局。
大血管入路后血管闭合最常采用外科切开和修复术。
2008 年 11 月至 2010 年 9 月,58 例严重主动脉瓣狭窄患者采用逆行股动脉入路行经导管 Edwards-SAPIEN 瓣膜置换术。其中 56 例采用“预闭”技术和 10-F Prostar 系统行 CBOT 治疗。评估该新型 CBOT 的技术成功率及 30 天临床事件(包括全因死亡率、主要血管并发症和大出血(根据 Valve Academic Research Consortium 标准的改良版本定义)的发生率)。
除 3 例患者(94.6%)外,其余患者均成功闭合。30 天死亡率、主要血管并发症和大出血发生率分别为 7.1%、14.3%和 5.4%。无死亡与入路部位并发症直接相关。14 例患者(25%)在指数住院期间至少接受了 1 次输血,其中 8 例(57.1%)与血管并发症无关。平均和中位数住院时间分别为 7.8 天和 6.0 天。
该新型经皮辅助 CBOT 联合 Prostar PCD 可使大多数 TAVI 后患者的经皮闭合安全、有效。